Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized forward of the pharmaceutical big’s earnings later this month, although the talks stay on monitor, in accordance with folks conversant in the matter.
The Wall Avenue Journal reported earlier this month that Merck aimed to agree on a purchase order of the most cancers biotech inside a number of weeks, a plan that has since been delayed, the folks stated.
